Back to LLY Overview
NYQ · Valuation Lab
LLY
Eli Lilly and Company
Last$1168.77
Market cap—
EV/EBITDA28.7x
Intrinsic value
$5345403380931.95
MoS +100.0% · Undervalued
Assuming 12.7% FCF margin and 55.5% Y1–5 growth.
Upside to price
EV (DCF)5.4T
Terminal share86%
Expected IV$5217771457884.25
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 86% of EV
PV of stage FCFs732.6B
PV of terminal value4.7T
Enterprise value5.4T
Net cash / (debt)-38.1B
Equity value5.3T
Intrinsic value / share$5345403380931.95
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 112.3B | 14.3B | 13.5B | 94.3% |
| Y2 | 174.7B | 22.2B | 19.7B | 89.0% |
| Y3 | 271.7B | 34.5B | 29B | 84.0% |
| Y4 | 422.4B | 53.6B | 42.5B | 79.2% |
| Y5 | 656.9B | 83.4B | 62.3B | 74.7% |
| Y6 | 839.5B | 106.6B | 75.2B | 70.5% |
| Y7 | 1.1T | 136.3B | 90.6B | 66.5% |
| Y8 | 1.4T | 174.1B | 109.3B | 62.7% |
| Y9 | 1.8T | 222.5B | 131.7B | 59.2% |
| Y10 | 2.2T | 284.4B | 158.8B | 55.8% |
| Terminal | — | — | 4.7T | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.